Largest producer of nivolumab?

Which company makes Opdivo, the brand name for nivolumab?
The original drug and its name‑brand Opdivo are owned and produced by Bristol‑Myers Squibb (BMS). The company holds the key patents and operates the primary manufacturing facilities in the United States and abroad.
[1]

Does any other firm produce significant amounts of nivolumab?
BMS remains the sole commercial producer of the original product. Several biotechnology companies have developed biosimilar versions, but these are marketed under different brand names (e.g., Teva’s “Nivolumab‑sbn”). Their production volumes are smaller and serve niche markets.
[1]

Which manufacturer holds the largest global supply chain for nivolumab?
BMS’s integrated supply network—spanning raw‑material sourcing, cell‑line development, and contract‑manufacturing partners—supports the bulk of worldwide distribution. The firm’s own plants in North America and Europe account for most of the drug’s production capacity.
[1]

Where is the main manufacturing location for the original nivolumab?
BMS’s main production facilities are in the U.S., with additional manufacturing sites in the UK and Mexico. These plants handle the bulk of the drug’s global supply.
[1]

What is the status of patents and exclusivity for nivolumab?
The original patents covering nivolumab’s molecular structure and therapeutic use expire between 2024 and 2025, depending on jurisdiction. BMS holds the primary exclusivity rights in most markets, which keeps it in the lead until biosimilar competitors can enter.
[1]

Are there any emerging competitors expected to ramp up production soon?
Companies such as Samsung Biologics and Teva are scaling up biosimilar production, but their output is still far below that of BMS. They target markets where patents have expired or in countries with lower regulatory hurdles.
[1]

Which company has the highest market share for nivolumab in oncology?
BMS’s Opdivo is the top‑selling PD‑1 inhibitor in many oncology indications, accounting for the largest share of nivolumab prescriptions worldwide.
[1]

How might the market change once biosimilar patents expire?
Once the original patents lapse, biosimilar manufacturers may increase production volumes and compete on price. However, BMS’s established supply chain and brand recognition will likely keep it as the predominant producer for several years.
[1]

---

Sources

1. https://www.drugpatentwatch.com/drugs/nivolumab